CTi Biopharma — Investor Presentation (September 2022)
24 slides from CTi Biopharma's investor presentation, Sep 28, 2022
Slide 1: September 2022 Corporate Deck
September 2022 Corporate Deck Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or
Slide 3: CTI Overview
CTI Overview *Continued approval may depend on demonstrating a clinical benefit in the PACIFICA trial. 1. NCCN® Clinical Practice Guidelines for Myeloproliferative Neoplasms V2 2022. 2. Evaluate Pharma, 2019 US Sales by Indication. ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. VONJO® (pacritinib) f
Slide 4: Cytopenic Patients are the Largest Segment of MF
Cytopenic Patients are the Largest Segment of MF 1. Evaluate Pharma, 2019 US Sales by Indication. 2. Prevalent population. 3. Masarova et al. Leukemia Research 2020;91:106338. 4. Nicolosi M, et al. Leukemia. 2018;32:1254-1258. 5. Harrison CN, et al. Leukemia 2016;30:1701-1707. 6. In a randomised Pha
Slide 5: The Needs of the Myelofibrosis Market
The Needs of the Myelofibrosis Market ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. 1. Data on file: ATU research among 100 MF treaters conducted by Kantar, 2021. 2. TriNetX, Dataworks US EMR Database, December 2020. 3. JAKAFI U.S. Package Insert (September 2021). MF Treaters Satisfaction with JAKA
Slide 6: The Unique Profile of VONJO
The Unique Profile of VONJO 1. Jarocha J, et al. Blood 2018;132(Supplement 1):2559. 2. Mascarenhas J, et al. Haematologica 2017;102(2):327-335. 3. Singer J, et al. Abstract #1874. Oral presentation ASH 2014. 4. Fisher D, et al. Leukemia 2019;33(8):1978-1995. 5. Lai HY, et al. Blood Adv 2019;3(2):122
Slide 7: VONJO: Now Approved in the U.S.
VONJO: Now Approved in the U.S. ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. U.S. Prescribing Information for VONJO (pacritinib) February 2022. REMS = Risk Evaluation and Mitigation Strategies programs. www.vonjo.com U.S. Prescribing Information Overview No Black Box Warning or REMS Program
Slide 8: VONJO: Proven Safety in Cytopenic Myelofibrosis
VONJO: Proven Safety in Cytopenic Myelofibrosis VONJO has a predictable and manageable safety profile in PERSIST-2 (platelet counts ≤100 × 109/L) ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. Most Common Adverse Reactions Warnings and Precautions Hemorrhage Diarrhea Thrombocytopenia Prolonged QT in
Slide 9: PACIFICA: Our Confirmatory Clinical Trial
PACIFICA: Our Confirmatory Clinical Trial ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. SVR, ≥35% spleen volume reduction; TSS, ≥50% reduction in total symptom score. SVR powering assumes the response rate is 3% in the P/C treatment arm, 19% in the pacritinib arm. TSS powering assumes the response
Slide 10: PERSIST-2: The Quintessential Study of Cytopenic MF
PERSIST-2: The Quintessential Study of Cytopenic MF1 1. Mascarenhas J, et al. JAMA Oncol. 2018;4(5):652-659. SVR, spleen volume reduction; TSS, total symptom score. PERSIST-2 is the only randomized, active-controlled, Phase 3 study in patients with platelet counts ≤100 x 109/L1 ©2022 CTI BIOPHARMA.
Slide 11: VONJO: Potential Best in Class for Reducing Spleen Size
VONJO: A Potential Best in Class Treatment for Reducing Spleen Size in Cytopenic Myelofibrosis ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. Median Percentage Change from Baseline in Spleen Volume at Week 24 in Patients with Platelet Counts <50 × 109/L Percentage of ITT Patients with Platelet Count
Slide 12: VONJO: Potential Best in Class for Symptom Relief
VONJO: A Potential Best in Class Treatment for Symptom Relief in Cytopenic Myelofibrosis ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. Median Percent Change From Baseline in Modified MFSAF v2.0 at Week 24 in Patients With <50 × 109/L Platelet Counts Percentage of ITT Patients with Platelet Counts <
Slide 13: The Anemia Benefit of VONJO (PERSIST-2)
The Anemia Benefit of VONJO (PERSIST-2) BAT=best available therapy; BID=twice daily; BL=baseline; Hgb=hemoglobin; PAC=pacritinib; RBC=red blood cell. 1. Mascarenhas J, et al. JAMA Oncol. 2018;4(5):652-659. 2. Gale RP, et al. Leuk Res. 2011;35:8-11. Among pts with baseline Hgb <10 g/dL, increase of H
Slide 14: VONJO Demonstrates Hematologic Stability (PERSIST-2)
Platelet Count Levels Through Week 24 Hemoglobin Levels Through Week 24 VONJO Demonstrates Hematologic Stability (PERSIST-2) Date on file. Supportive care was permitted on the BAT arm. No conclusions regarding the benefits or risks of VONJO can be established based on these data from PERSIST-2. Thes
Slide 15: Pacritinib is a Highly Potent Inhibitor of ACVR1
Pacritinib is a Highly Potent Inhibitor of ACVR1 1. Oh S, et al. SOHO 2022; Poster MPN-145. ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION.
Slide 16: Anemia Benefit of Pacritinib Potentially Related to ACVR1 and IRAK-1
Anemia Benefit of Pacritinib Potentially Related to Inhibition of ACVR1 and IRAK-1 ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. 1. Oh S, et al. SOHO 2022; Abstract MPN-145.
Slide 17: Pacritinib Improves Transfusion Independence (TI)
Pacritinib Improves Transfusion Independence (TI) PACRITINIB (PERSIST-2) Transfusion Independence (TI) in non-Ti patients Momelotinib (Momentum) Improvement in TI and transfusion rate among patients who required RBC transfusions at baseline Patients with an available 24-week visit (evaluable) who we
Slide 18: The VONJO Commercial Launch is Underway
The VONJO Commercial Launch is Underway ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. Field Deployment Market Segmentation Coverage and Access The VONJO Launch is Fully Funded and Underway Payors recognize the unmet need Expanding coverage to label Part of NCCN® treatment guidelines 80% of patients
Slide 19: VONJO: Included in NCCN Oncology Guidelines
VONJO: Included in NCCN Oncology Guidelines Pacritinib recommendations include first- and second-line usage1 Treatment for all high-risk myelofibrosis patients (first- and second-line) with platelet counts <50 x 109/L who are not candidates for transplant Second-line treatment for lower-risk and hig
Slide 20: The Key Drivers for VONJO Launch Success
The Key Drivers for VONJO Launch Success ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. Building Awareness Educate on the prevalence of cytopenic myelofibrosis Discuss the challenges faced in treating cytopenic myelofibrosis patients Raise awareness of the limitations of current therapies Demonstrat
Slide 21: VONJO: Optimizing Cytopenic MF Therapy
VONJO: Optimizing Cytopenic MF Therapy ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. Potential Best in Class Benefit Only JAK inhibitor to demonstrate meaningful clinical benefit in cytopenic myelofibrosis Also inhibits IRAK1 and ACVR1 Safe, simple and effective Convenient Dosing Oral medication Fu
Slide 22: Our Strong Financial Position
Our Strong Financial Position ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. Fully funded launch and commercialization *Assumes all preferred stock has been converted to common stock. Preferred stock has equivalent economic value to common stock. Balance Sheet 06/30/2022 12/31/2021 Cash, Cash Equiva
Slide 23: CTI: Ready for Successful Commercialization
CTI: Ready for Successful Commercialization ©2022 CTI BIOPHARMA. CONFIDENTIAL INFORMATION. Strong Financial Position Fully funded commercial launch $95.9 M cash at end of 2Q22 Well Defined Market Compelling product label Safe, simple and effective Substantial market opportunity Leading the Way in Cy
Slide 24: 3101 Western Ave., Seattle, WA 98121
3101 Western Ave., Suite 800 Seattle, WA 98121
CTI BioPharma — Investor Presentation (September 2022) on 6ix